JP2008503475A - メマンチンの放出が改変された製剤 - Google Patents

メマンチンの放出が改変された製剤 Download PDF

Info

Publication number
JP2008503475A
JP2008503475A JP2007516725A JP2007516725A JP2008503475A JP 2008503475 A JP2008503475 A JP 2008503475A JP 2007516725 A JP2007516725 A JP 2007516725A JP 2007516725 A JP2007516725 A JP 2007516725A JP 2008503475 A JP2008503475 A JP 2008503475A
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
solid
release
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007516725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008503475A5 (cg-RX-API-DMAC7.html
Inventor
ラストゥギー・サニエル・ケイ．
レオ・ニラーンジャン
ペリクロウ・アントニア
エイブラモウィッツ・ワタッナポーン
ディディーヤ・マハーンドラ・ジー．
マハーシャブデ・シャシャンク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forest Laboratories LLC
Original Assignee
Forest Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008503475(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories LLC filed Critical Forest Laboratories LLC
Publication of JP2008503475A publication Critical patent/JP2008503475A/ja
Publication of JP2008503475A5 publication Critical patent/JP2008503475A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007516725A 2004-06-17 2005-06-16 メマンチンの放出が改変された製剤 Pending JP2008503475A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58124204P 2004-06-17 2004-06-17
PCT/US2005/021260 WO2006009769A1 (en) 2004-06-17 2005-06-16 Modified release formulation of memantine

Publications (2)

Publication Number Publication Date
JP2008503475A true JP2008503475A (ja) 2008-02-07
JP2008503475A5 JP2008503475A5 (cg-RX-API-DMAC7.html) 2011-02-24

Family

ID=34972465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007516725A Pending JP2008503475A (ja) 2004-06-17 2005-06-16 メマンチンの放出が改変された製剤

Country Status (11)

Country Link
US (9) US8039009B2 (cg-RX-API-DMAC7.html)
EP (1) EP1781261A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008503475A (cg-RX-API-DMAC7.html)
CN (1) CN1968684A (cg-RX-API-DMAC7.html)
AU (1) AU2005265031A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512177A (cg-RX-API-DMAC7.html)
CA (1) CA2569015A1 (cg-RX-API-DMAC7.html)
EA (1) EA011446B1 (cg-RX-API-DMAC7.html)
IL (1) IL179991A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06014587A (cg-RX-API-DMAC7.html)
WO (1) WO2006009769A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017178963A (ja) * 2013-07-30 2017-10-05 ギリアード コネチカット， インコーポレイテッド Ｓｋｙ阻害剤の製剤
JPWO2016121664A1 (ja) * 2015-01-26 2017-11-02 第一三共株式会社 ピロールカルボキサミドの固形組成物
JP2023551249A (ja) * 2020-11-24 2023-12-07 セントロ デ ネウロシエンシアス デ キューバ、セネウロ アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
WO2006138227A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US20070092577A1 (en) * 2005-10-03 2007-04-26 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
CA2681174C (en) 2007-03-22 2020-06-02 Guosong Liu Magnesium compositions and uses thereof
TW200916091A (en) * 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
EP2170310A4 (en) * 2007-06-29 2010-06-23 Orchid Chemicals & Pharm Ltd FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE
US20100215740A1 (en) 2007-10-10 2010-08-26 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
RU2012117898A (ru) 2009-09-30 2013-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Кофакторы и способы их применения индивидуумами
CN106389381A (zh) 2009-12-02 2017-02-15 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
WO2012101653A2 (en) 2011-01-25 2012-08-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
JP6158801B2 (ja) 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
CN103417483B (zh) * 2012-05-25 2017-09-12 杭州赛利药物研究所有限公司 盐酸美金刚缓释干混悬剂及其制备方法
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
IN2015DN01023A (cg-RX-API-DMAC7.html) 2012-08-16 2015-06-26 Teva Pharma
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
BR112015010947A2 (pt) 2012-11-13 2018-06-05 Nusirt Sciences Inc composições e métodos para aumentar o metabolismo energético.
CN105101958B (zh) 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
RU2015143836A (ru) 2013-03-15 2017-04-27 Нусерт Сайенсиз, Инк. Лейцин и никотиновая кислота для снижения уровня липидов
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
WO2015131152A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
EP3229789A4 (en) 2014-12-12 2018-08-08 Ojai Energetics PBC Microencapsulated cannabinoid compositions
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
CN120478294A (zh) 2015-10-16 2025-08-15 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
CN105412047A (zh) * 2015-12-03 2016-03-23 烟台东诚药业集团股份有限公司 一种骨架型盐酸美金刚缓释胶囊及其制备方法
EA201990032A1 (ru) 2016-06-15 2019-06-28 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Способы и композиции для терапии посредством потенциирования стволовых клеток
EP3471745B1 (en) 2016-06-15 2025-03-26 Ojai Energetics PBC Compositions for reducing oxidative stress
RU2623865C1 (ru) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
RU2654713C1 (ru) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
CA3086163A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
CN113597306A (zh) 2018-12-18 2021-11-02 奥海能量公益公司 用于虚拟现实和增强现实体验的大麻素组合物
US20220133650A1 (en) * 2019-02-06 2022-05-05 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Combination therapy for treatment of brain disorders
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
WO2020208398A1 (es) 2019-04-09 2020-10-15 Laboratorios Bagó S.A. Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10966989B2 (en) * 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
US20240082204A1 (en) * 2022-09-09 2024-03-14 Zyvran Pharmaceuticals Treatment composition for mild cognitive impairment and dementia
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63290818A (ja) * 1987-03-11 1988-11-28 レツク・トバルナ・フアルマセブトスキー・イン・ケミクニー・イジエルコブ・エヌ・ソル・オー 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤
JP2004515477A (ja) * 2000-12-07 2004-05-27 ニューロモレキュラー インコーポレイテッド Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (cg-RX-API-DMAC7.html) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
AU729529B2 (en) 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ES2200358T3 (es) 1997-06-30 2004-03-01 MERZ PHARMA GMBH & CO. KGAA 1-amino-alquilciclohexanos antagonistas del receptor de nmda.
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006138227A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
WO2009151498A2 (en) 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63290818A (ja) * 1987-03-11 1988-11-28 レツク・トバルナ・フアルマセブトスキー・イン・ケミクニー・イジエルコブ・エヌ・ソル・オー 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤
JP2004515477A (ja) * 2000-12-07 2004-05-27 ニューロモレキュラー インコーポレイテッド Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017178963A (ja) * 2013-07-30 2017-10-05 ギリアード コネチカット， インコーポレイテッド Ｓｋｙ阻害剤の製剤
JPWO2016121664A1 (ja) * 2015-01-26 2017-11-02 第一三共株式会社 ピロールカルボキサミドの固形組成物
JP2023551249A (ja) * 2020-11-24 2023-12-07 セントロ デ ネウロシエンシアス デ キューバ、セネウロ アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物

Also Published As

Publication number Publication date
CA2569015A1 (en) 2006-01-26
US20150148427A1 (en) 2015-05-28
US20130310460A1 (en) 2013-11-21
MXPA06014587A (es) 2007-04-27
EP1781261A1 (en) 2007-05-09
US8039009B2 (en) 2011-10-18
EA200700049A1 (ru) 2007-04-27
US20140213659A1 (en) 2014-07-31
EA011446B1 (ru) 2009-02-27
IL179991A0 (en) 2007-05-15
CN1968684A (zh) 2007-05-23
US10660868B2 (en) 2020-05-26
US20160324803A1 (en) 2016-11-10
AU2005265031A1 (en) 2006-01-26
BRPI0512177A (pt) 2008-02-12
WO2006009769A1 (en) 2006-01-26
US20130012593A1 (en) 2013-01-10
US20200268685A1 (en) 2020-08-27
US20150258031A1 (en) 2015-09-17
US20060051416A1 (en) 2006-03-09
US20120004318A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
US20200268685A1 (en) Modified release formulations of memantine oral dosage forms
JP4758064B2 (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
EP2405915B1 (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
RU2422135C2 (ru) Матричная таблетка с модифицированным высвобождением нерамексана
WO2009086046A1 (en) Orally disintegrating tablet compositions of temazepam
EP3744320A1 (en) Pharmaceutical tablet composition comprising edoxaban
JP5025468B2 (ja) メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
WO2014134221A1 (en) Compositions and methods for treatment in parkinson's disease patients
EP3854386B1 (en) An orally disintegrating pharmaceutical composition comprising nefopam and process for preparing the same
WO2009027786A2 (en) Matrix dosage forms of varenicline
KR20080059212A (ko) 3-(2-디메틸아미노메틸 사이클로헥실) 페놀 지연 제형
KR20070023743A (ko) 메만틴의 조절된 방출 제제
CN118201603A (zh) 多颗粒药物组合物
CN120076797A (zh) 包含去铁酮的调释药物制剂
HK1103972A (en) Modified release formulation of memantine
MXPA06014586A (en) Drinkableimmediate release tablet made with direct compression of memantine or neramexane
KR20180089811A (ko) 프레가발린 함유 고팽윤성 서방성 삼중정제
HK1148696A (en) Orally disintegrating tablet compositions of temazepam

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101227

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025